Kevin McRaith

President and Chief Executive Officer Welldoc

Last Reviewed: September 26, 2026

Executive Summary

Kevin McRaith is President and Chief Executive Officer of Welldoc, the Columbia, Maryland company that builds AI-powered digital coaching for people living with diabetes, obesity, hypertension, heart failure and related conditions, and holds 11 FDA 510(k) clearances. He arrived in March 2014 as President under the then CEO and within the year was signing the company’s securities filings as Chief Executive Officer, a role he has now held for more than a decade. His background is commercial rather than technical: sales and marketing leadership in biotech and pharmaceuticals at Human Genome Sciences, Genentech and Abbott.

Career Highlights

• President and Chief Executive Officer of Welldoc, per its leadership page and 2026 press releases.
• Signed WellDoc’s SEC Form D as Chief Executive Officer in December 2014, nine months after joining.
• Joined WellDoc as President in March 2014, reporting to then-CEO Ryan Sysko.
• Led Welldoc’s entry into the CMS ACCESS Model as a credentialed Medicare Part B supplier, announced July 2026.
• Previously Vice President, Sales & Marketing at Human Genome Sciences, with similar leadership roles at Genentech and Abbott.
• Began his career at Baxter Healthcare.

Professional Journey

McRaith started his career at Baxter Healthcare and moved into commercial leadership in life sciences, holding sales and marketing leadership roles at Abbott and Genentech before becoming Vice President, Sales & Marketing at Human Genome Sciences. Welldoc describes this as more than 25 years spent across biotech, pharmaceuticals and digital health.

In March 2014 he joined WellDoc, then based in Baltimore, as President, reporting to Chief Executive Officer Ryan Sysko. The company was known for BlueStar, which it describes as the first FDA-cleared digital therapeutic. By December 2014 McRaith was signing WellDoc’s Form D filings with the SEC as Chief Executive Officer, and by 2016 he was also listed as a director, alongside board members representing Samsung, Excel Venture Fund and the Merck Global Health Innovation Fund.

Under his leadership Welldoc has broadened from diabetes into a wider cardiometabolic platform covering pre-diabetes, hypertension, heart failure and weight and obesity management, including support for people on GLP-1 medicines, with integrated mental wellbeing and sleep support. The company says it partners with health plans, health systems and employers. In July 2026 the company announced it had gone live on the Centers for Medicare & Medicaid Services’ ACCESS Model as a credentialed Medicare Part B supplier; McRaith called the model “a pivotal milestone in the modernization of chronic care”.

Education

No education record was found in Welldoc’s biography, the 2014 appointment announcement or the SEC filings reviewed.